Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing Co's EBIT per Share for the
three
months ended in Jun. 2026 was HK$0.35.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$1.39.
During the past 12 months, the average EBIT per Share Growth Rate of Pharmaron Beijing Co was 6.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 8.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 13.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 21.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Pharmaron Beijing Co's EBIT per Share or its related term are showing as below:
HKSE:03759'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 6.4 Med: 23.5 Max: 42.2
Current: 8.4
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Pharmaron Beijing Co was 42.20% per year. The lowest was 6.40% per year. And the median was 23.50% per year.
HKSE:03759's 3-Year EBIT Growth Rate is ranked worse than 58.67% of 1171
companies
in the Biotechnology industry
Industry Median: 15.4
vs HKSE:03759: 8.40
Pharmaron Beijing Co (HKSE:03759) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Pharmaron Beijing Co EBIT per Share Related Terms
Pharmaron Beijing Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (HKSE:03759) has a EBIT per Share of HK$1.39 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharmaron Beijing Co and its competitors. According to the industry distribution chart, Pharmaron Beijing Co ranks #687 out of 1171 companies in the Biotechnology industry, placing it in the top 58.7%.
Is Pharmaron Beijing Co's EBIT per Share too high?
Pharmaron Beijing Co's current EBIT per Share is HK$1.39. Based on the distribution chart, Pharmaron Beijing Co ranks #687 out of 1171 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmaron Beijing Co has a GF Score™ of 89/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #687 out of 1171 companies for EBIT per Share. This places Pharmaron Beijing Co in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current EBIT per Share is HK$1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$21.84, compared to a current price of HK$28.64 — trading 31.1% above its estimated fair value. The current EBIT per Share is HK$1.39. Pharmaron Beijing Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current EBIT per Share is HK$1.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of HK$28.64 is trading 31.1% above its estimated GF Value™ of HK$21.84.
GuruFocus considers Pharmaron Beijing Co to be Significantly Overvalued.
Key valuation signals for HKSE:03759:
EBIT per Share: HK$1.39
GF Value™: HK$21.84 vs. price of HK$28.64 (31.1% above fair value)
No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
89GF Score
Get the complete analysis for HKSE:03759
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03759 has been successfully added to your 
